Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study

Joseph J. Eron, Bonaventura Clotet, Jacques Durant, Christine Katlama, Princy Kumar, Adriano Lazzarin, Isabelle Poizot-Martin, Gary Richmond, Vincent Soriano, Mounir Ait-Khaled, Tamio Fujiwara, Jenny Huang, Sherene Min, Cindy Vavro, Jane Yeo, Sharon L. Walmsley, Joseph Cox, Jacques Reynes, Philippe Morlat, Daniel VittecoqJean Michel Livrozet, Pompeyo Viciana Fernández, Jose M. Gatell, Edwin DeJesus, Jerome DeVente, Jacob P. Lalezari, Lewis H. McCurdy, Louis A. Sloan, Benjamin Young, Anthony LaMarca, Trevor Hawkins

Research output: Contribution to journalArticle

Abstract

Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance.Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was

Original languageEnglish
Pages (from-to)740-748
Number of pages9
JournalJournal of Infectious Diseases
Volume207
Issue number5
DOIs
Publication statusPublished - Mar 1 2013

    Fingerprint

Keywords

  • Dolutegravir
  • DTG
  • integrase inhibitor
  • raltegravir resistance
  • S/GSK1349572

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C., Yeo, J., Walmsley, S. L., Cox, J., Reynes, J., Morlat, P., ... Hawkins, T. (2013). Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study. Journal of Infectious Diseases, 207(5), 740-748. https://doi.org/10.1093/infdis/jis750